

PERSONAL INFORMATION

Caridad Pontes

WORK EXPERIENCE

January 2011-June 2016

Consultant physician. Responsible for the Clinical Pharmacology Unit.

Corporació Sanitària Parc Taulí (Spain)

Member of the Ethics Committee for Clinical Research. Member of the Institutional Committee of Pharmacotherapeutics. Hospital Pharmacovigilance. Methodological support to clinical research projects. Drug utilization studies. Drug selection and drug information.

June 2016- Present

Medicines manager

Servei Català de la Salut (Spain)

Catalan Health System, medicines manager since 2020. Formerly in charge of appraisal of therapeutic value, drug positioning and decision on criteria for access to innovative medicines.

December 2010- Present

Associate Professor

Universitat Autònoma de Barcelona (Spain)

Department of Pharmacology, Toxicology and Therapeutics.

Teaching and coordination of Pharmacology and Clinical Pharmacology at the Teaching Unit Parc Taulí, School of Medicine of Universitat Autònoma de Barcelona.

December 2006-December 2010

Head of Clinical Research & Regulatory Affairs

Palau Pharma S.A. (Spain)

Technical and managerial responsibility on Clinical research and Regulatory Affairs for the company, reporting to the Drug Development and Clinical Research Director. Member of the Management Board.

Responsible for planning, design and execution of clinical development plans for new chemical entities, focused on early clinical development from first into man to proof of concept, in the areas of dermatology, gastroenterology, analgesia and respiratory. Responsible for IMPDs, IBs, briefing documents and regulatory interactions with Regulatory Agencies.

Responsible person for Eudravigilance and Pharmacovigilance for the company.

Responsible for implementation and maintenance of GCP in the newly created department, including set-up and management of SOPs.

Collaboration with the Business Development Department for technical support to the the licensing out of products, to technical follow-up of licensed products, and to assess licensing opportunities, including due diligences.

May 2004-November 2006

Senior Scientist. Pharmacovigilance, Pharmacoepidemiology & Pharmacoconomics.

Procter & Gamble Pharmaceuticals (Spain)

Qualified Person for PV in Spain. Pharmacovigilance contact person for the Spanish Medicines Agency. Review of monthly symptom frequency report, SAE listings and compliance reports. Review of PSURs for local products.

Pharmacovigilance Physician: medical support to the European Qualified Person for pharmacovigilance. Assessment of medical significance of suspected adverse reactions. Medical evaluation of safety data, individual and aggregate patient safety data in reports and summaries for clinical studies and marketed products.

Deputy Qualified Person for Pharmacovigilance in Europe: medical support to a non-medical European Qualified Person, and back-up QP-PV role. Overview of PV systems and follow-up of

system audits. Review of monthly symptom frequency report, SAE listings and compliance reports for local affiliates. Review of PSURs for European local and global products. Participation in PV Safety Analysis Group meetings. Ongoing review of all SAE reports.

Pharmacoepidemiology responsible for Europe: Pharmacoepidemiology activities for marketed products and support for products in Phase II, III, and IV projects, including input to Risk Management Plans. Analyses of population Health Care Databases (GPRD). Other epidemiologic initiatives across P&G as needed.

January 2002-May 2004 **Head of Clinical Pharmacology**

Laboratorios Vita S.A (Spain)

Technical support and management of the Section (1 MD clinical monitor, 1 MD safety officer for investigational products, 1 CRA and 1 administrative). SOP update and creation; training and follow-up of quality control procedures.

Planning, design and conduction of clinical development plans and clinical trials from phase I to III-b with innovative products of the company in the areas of cardiovascular, analgesia and metabolism, in diverse European countries and the USA. Bioequivalence studies with generic products.

Supervision of data management and statistics.

Integrated safety data analyses for investigational products. Technical support to the Medical Department for the design, conduction and analysis of phase IV studies, and to the Post-Marketing Safety Officer for the assessment of SAE, elaboration of PSUR and reporting of phase IV data.

Clinical support to Regulatory Affairs during local and EU Marketing Authorisation Applications by Mutual Recognition Procedure; also for the elaboration and requests of PEI (Investigational New Product qualification) to the Spanish Agency of Medicines and IND to the FDA.

Collaboration with the Medical and Marketing Departments: communication of clinical results to opinion leaders and congresses; technical support for the launch of an antihypertensive product.

Support to the Business Development and Licensing Department: for the technical evaluation of new licenses "in" and presentation of the medical aspects of licenses "out".

September 1996-December 2001 **Head of the Clinical Pharmacology Department, R&D Area**

J Uriach & Cia S.A. (Spain)

Exploratory development of new products (anti-inflammatory drug for IBD, COX-2 inhibitor, systemic antifungal drug). Responsible for planning and conduction of clinical trials from phase I to early phase II with these products. Responsible scientist consultant for a NCE for IBD within R&D: technical co-ordination of a multidisciplinary team for project planning; identification and co-ordination of a Scientific Advisory Panel; technical communication of the project.

Previously: Project leader for the completion of the development of a new vaginal antifungal drug already in clinical phase II until launch: analysis of the technical and commercial viability of the project. Definition of the project specifications, planning of the execution phase and co-ordination of the project team; detection and correction of problems, and progress reporting to management.

Previously: Monitoring and design of clinical trials from phases I to III in the areas of dermatology and gynecology (topical antifungal drug), cardiovascular (NCE for hypertension; antiaggregant drug for AMI and stroke prevention) and allergy (antihistaminic drug). Responsible for study planning, protocol writing, CRAs support and financial follow-up of the project. ICH report writing; communication and publication of results. Expert reporting. Special background in data management and statistics; collaboration in the implantation of the ClinTrial application for data management and in the process of standardisation of data modules and statistical analysis in clinical trials.

Clinical support to Regulatory Affairs during local Marketing Authorisation Applications and during MRP for an antihistaminic product for allergic rhinitis and a topical antifungal drug for dermatomycoses. Request of Scientific advice to the Spanish Medicines Agency for new indications for a topical antifungal product.

EDUCATION AND TRAINING

December 1999-October 2004

PhD in Medicine and Surgery

Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona (Spain)

Doctoral thesis: 'Risk of colorectal cancer: relationship with previous exposure to drugs. Case-Control study.'

Department of Epidemiology and Public Health. Institut Català d'Oncologia, Hospital Duran i Reynals // Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona

Defended in October 2004 : Excel.lent Cum Laude.

September 1984-June 1990

MD

Universitat Autònoma de Barcelona (Spain)

Degree in Medicine and Surgery

January 1991-December 1994

Medical specialist in Clinical Pharmacology

Ministerio de Sanidad y Consumo (Spain)

Medical internship at Hospital Universitari Vall d'Hebron

ADDITIONAL INFORMATION

Expertise

Clinical Pharmacology, Clinical Development, Clinical Research, Early Clinical Development and Translational Medicine. Development Planning. Regulatory Affairs. Health Technology Appraisal, Drug pricing and reimbursement.

Statistics and Methodology, Clinical Trials.

Pharmacovigilance and Pharmacoepidemiology. Pharmacokinetics and Drug information.

Orphan drugs.

Research Project Management, Medical Writing, Medical Education, Managerial Experience

Publications

1. Brunet E, Vela E, Melcarne L, Clèries M, Pontes C, Llovet LP, García-Iglesias P, Gallach M, Villòria A, Vergara M, Calvet X. Time Trends of Crohn's Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery. *J Clin Med*. 2020 Sep 8;9(9). doi: 10.3390/jcm9092896. PubMed PMID: 32911630; PubMed Central PMCID: PMC7563515.
2. Bakkum MJ, Tichelaar J, Papaioannidou P, Likic R, Sanz Alvarez EJ, Christiaens T, Costa JN, Maiulaitis R, Dima L, Coleman J, Richir MC, van Agtmael MA. Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics. *Br J Clin Pharmacol*. 2020 Jul 7;. doi: 10.1111/bcp.14453. [Epub ahead of print] PubMed PMID: 32638391.
3. Roig Izquierdo M, Prat Casanovas MA, Gorgas Torner MQ, Pontes García C. Registry of patients and treatments of hospital medicines in Spain: 10 years of clinical data. *Med Clin (Barc)*. 2020 Mar 13;154(5):185-191. doi: 10.1016/j.medcli.2019.09.009. Epub 2019 Nov 20. PubMed PMID: 31759696.
4. Vinson D, Molet-Benhamou L, Degboé Y, den Broeder A, Ibrahim F, Pontes C, Westhovens R, Závada J, Pham T, Barnetche T, Constantin A, Ruysse-Witrand A. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. *Arthritis Res Ther*. 2020 Apr 29;22(1):97. doi: 10.1186/s13075-020-02188-x. PubMed PMID: 32349791; PubMed Central PMCID: PMC7191828.
5. Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. *Appl Health Econ Health Policy*. 2020 Feb;18(1):5-16. doi:

10.1007/s40258-019-00527-x. PubMed PMID: 31696433.

6. Ibáñez-Sanz G, Guinó E, Pontes C, Morros R, de la Peña-Negro LC, Quijada-Manuitt MÁ, Moreno V. Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records. *Eur J Epidemiol.* 2020 Jan;35(1):37-48. doi: 10.1007/s10654-019-00584-5. Epub 2019 Nov 16. PubMed PMID: 31734885.

7. Escamilla Y, Cardesín A, Samara L, López S, Izquierdo A, Fradera M, Vives R, Bernal-Sprekelsen M, Pontes C. Randomized clinical trial to compare the efficacy to improve the quality of surgical field of hypotensive anesthesia with clonidine or dexmedetomidine during functional endoscopic sinus surgery. *Eur Arch Otorhinolaryngol.* 2019 Nov;276(11):3095-3104. doi: 10.1007/s00405-019-05575-6. Epub 2019 Jul 30. PubMed PMID: 31363901.

8. Moreno M, Arévalo M, Zamora M, Pontes C, Oliva JC, Gratacós J. Comparison of disease activity in patients with ankylosing spondylitis under TNFi or NSAID treatment, is there any difference? An observational study. *Reumatol Clin.* 2019 Sep 24;. doi: 10.1016/j.reuma.2019.07.005. [Epub ahead of print] PubMed PMID: 31558361.

9. Ibáñez-Sanz G, Guinó E, Pontes C, Quijada-Manuitt MÁ, de la Peña-Negro LC, Aragón M, Domínguez M, Rodríguez-Alonso L, Blasco A, García-Rodríguez A, Morros R, Moreno V. Statin use and the risk of colorectal cancer in a population-based electronic health records study. *Sci Rep.* 2019 Sep 19;9(1):13560. doi: 10.1038/s41598-019-49877-5. PubMed PMID: 31537841; PubMed Central PMCID: PMC6753123.

10. van der Voort T, Brinkman DJ, Benemei S, Böttiger Y, Chamontin B, Christiaens T, Likic R, Maiulaitis R, Marandi T, Monteiro EC, Papaioannidou P, Pers YM, Pontes C, Raskovic A, Regenthal R, Sanz EJ, Wilson K, Tichelaar J, van Agtmael MA. Appropriate antibiotic prescribing among final-year medical students in Europe. *Int J Antimicrob Agents.* 2019 Sep;54(3):375-379. doi: 10.1016/j.ijantimicag.2019.05.008. Epub 2019 May 7. PubMed PMID: 31075400.

11. Molina A, Vicente M, Gasol M, Carbonell P, López P, Pontes C. A Drug Utilization Study of Sacubitril/Valsartan in Catalonia. *Rev Esp Cardiol (Engl Ed).* 2019 Jul;72(7):593-595. doi: 10.1016/j.rec.2018.08.004. Epub 2018 Aug 29. PubMed PMID: 30172655.

12. Guarga L, Badia X, Obach M, Fontanet M, Prat A, Vallano A, Torrent J, Pontes C. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut). *Orphanet J Rare Dis.* 2019 Jun 27;14(1):157. doi: 10.1186/s13023-019-1121-6. PubMed PMID: 31248421; PubMed Central PMCID: PMC6598260.

13. Moreno M, Gratacós J, Torrente-Segarra V, Sanmartí R, Morlà R, Pontes C, Llop M, Juanola X. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. *Arthritis Res Ther.* 2019 Apr 5;21(1):88. doi: 10.1186/s13075-019-1873-3. PubMed PMID: 30953541; PubMed Central PMCID: PMC6451276.

14. Moreno M, Lisbona MP, Gallardo F, Deza G, Ferran M, Pontes C, Luelmo J, Maymó J, Gratacós J. Ultrasound Assessment of Psoriatic Onychopathy: A Cross-sectional Study Comparing Psoriatic Onychopathy with Onychomycosis. *Acta Derm Venereol.* 2019 Feb 1;99(2):164-169. doi: 10.2340/00015555-3060. PubMed PMID: 30281142.

15. Vives R, Fernandez-Galinski D, Gordo F, Izquierdo A, Oliva JC, Colilles C, Pontes C. Effects of bupivacaine or levobupivacaine on cerebral oxygenation during spinal anesthesia in elderly patients undergoing orthopedic surgery for hip fracture: a randomized controlled trial. *BMC Anesthesiol.* 2019 Jan 31;19(1):17. doi: 10.1186/s12871-019-0682-1. PubMed PMID: 30704463; PubMed Central PMCID: PMC6357488.

16. Gratacós J, Pontes C, Juanola X, Sanz J, Torres F, Avendaño C, Vallano A, Calvo G, de Miguel E, Sanmartí R. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. *Arthritis Res Ther.* 2019 Jan 8;21(1):11. doi: 10.1186/s13075-018-1772-z. PubMed PMID: 30621746; PubMed Central PMCID: PMC6323809.

17. Laso-Morales MJ, Vives R, Vallejo-Tarrat A, Caló N, Valle-Beltran A, Pontes C. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial. *Trials.* 2019 Jan 7;20(1):23. doi: 10.1186/s13063-018-3125-2. PubMed PMID: 30616657; PubMed Central PMCID: PMC6323815.

18. Brunet E, Roig-Ramos C, Vela E, Clèries M, Melcarne L, Villòria A, Pontes C, Calvet X. Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis. *Ann Med*. 2018 Nov;50(7):613-619. doi: 10.1080/07853890.2018.1523550. Epub 2018 Nov 19. PubMed PMID: 30247071.
19. Pontes C, Fontanet JM, Vives R, Sancho A, Gómez-Valent M, Ríos J, Morros R, Martinalbo J, Posch M, Koch A, Roes K, Oude Rengerink K, Torrent-Farnell J, Torres F. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. *Orphanet J Rare Dis*. 2018 Nov 15;13(1):206. doi: 10.1186/s13023-018-0926-z. PubMed PMID: 30442155; PubMed Central PMCID: PMC6238348.
20. Mitroiu M, Oude Rengerink K, Pontes C, Sancho A, Vives R, Pesiou S, Fontanet JM, Torres F, Nikolakopoulos S, Pateras K, Rosenkranz G, Posch M, Urach S, Ristl R, Koch A, Loukia S, van der Lee JH, Roes KCB. Applicability and added value of novel methods to improve drug development in rare diseases. *Orphanet J Rare Dis*. 2018 Nov 12;13(1):200. doi: 10.1186/s13023-018-0925-0. PubMed PMID: 30419965; PubMed Central PMCID: PMC6233569.
21. Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, Nikolakopoulos S, Vermeulen E, van der Lee JH. Rare disease registries: potential applications towards impact on development of new drug treatments. *Orphanet J Rare Dis*. 2018 Sep 5;13(1):154. doi: 10.1186/s13023-018-0836-0. PubMed PMID: 30185208; PubMed Central PMCID: PMC6126025.
22. Brinkman DJ, Tichelaar J, Mokkink LB, Christiaens T, Licik R, Maciulaitis R, Costa J, Sanz EJ, Maxwell SR, Richir MC, van Agtmael MA. Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. *Clin Pharmacol Ther*. 2018 Aug;104(2):317-325. doi: 10.1002/cpt.962. Epub 2018 Jan 30. PubMed PMID: 29205299; PubMed Central PMCID: PMC6099198.
23. Laso-Morales MJ, Vives R, Gómez-Ramírez S, Pallisera-Lloveras A, Pontes C. Intravenous iron administration for post-operative anaemia management after colorectal cancer surgery in clinical practice: a single-centre, retrospective study. *Blood Transfus*. 2018 Jul;16(4):338-342. doi: 10.2450/2018.0004-18. Epub 2018 Mar 5. PubMed PMID: 29517968; PubMed Central PMCID: PMC6034767.
24. Tafuri G, Lucas I, Estevão S, Moseley J, d'Andon A, Bruehl H, Gajraj E, Garcia S, Hedberg N, Massari M, Molina A, Obach M, Osipenko L, Petavy F, Petschulies M, Pontes C, Russo P, Schiel A, Van de Castele M, Zebedin-Brandl EM, Rasi G, Vamvakas S. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. *Br J Clin Pharmacol*. 2018 May;84(5):1013-1019. doi: 10.1111/bcp.13524. Epub 2018 Mar 5. PubMed PMID: 29370449; PubMed Central PMCID: PMC5903262.
25. Pontes C, Marsal JR, Elorza JM, Aragón M, Prieto-Alhambra D, Morros R. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population-based, Nested Case-control Study. *Clin Ther*. 2018 Feb;40(2):270-283. doi: 10.1016/j.clinthera.2017.12.011. Epub 2018 Feb 3. PubMed PMID: 29398161.
26. Puig-Comas G, García-Peláez M, Gorgas Torner MQ, Pontes García C. Serotonin syndrome during a heat wave. *Emergencias*. 2018 Feb;30(1):62-63. PubMed PMID: 29437313.
27. Quijada-Manuitt MA, Escamilla Y, Vallano A, Cardesín A, Bernal-Sprekelsen M, Pontes C. Use of 2-Adrenergic Agonists to Improve Surgical Field Visibility in Endoscopy Sinus Surgery: A Systematic Review of Randomised Controlled Trials. *Clin Ther*. 2018 Jan;40(1):136-149.e19. doi: 10.1016/j.clinthera.2017.11.010. Review. PubMed PMID: 29268957.
28. Laso-Morales M, Jericó C, Gómez-Ramírez S, Castellví J, Viso L, Roig-Martínez I, Pontes C, Muñoz M. Preoperative management of colorectal cancer-induced iron deficiency anemia in clinical practice: data from a large observational cohort. *Transfusion*. 2017 Dec;57(12):3040-3048. doi: 10.1111/trf.14278. Epub 2017 Aug 21. PubMed PMID: 28833205.
29. Torres F, Ríos J, Saez-Peñataro J, Pontes C. Is Propensity Score Analysis a Valid Surrogate of Randomization for the Avoidance of Allocation Bias?. *Semin Liver Dis*. 2017 Aug;37(3):275-286. doi: 10.1055/s-0037-1606213. Epub 2017 Aug 28. Review. PubMed PMID: 28847037.

30. Brinkman DJ, Tichelaar J, Schutte T, Benemei S, Böttiger Y, Chamontin B, Christiaens T, Likic R, Maiulaitis R, Marandi T, Monteiro EC, Papaioannidou P, Pers YM, Pontes C, Raskovic A, Regenthal R, Sanz EJ, Tamba BI, Wilson K, Vries T, Richir MC, Agtmael MV. Essential competencies in prescribing: A first european cross-sectional study among 895 final-year medical students. *Clin Pharmacol Ther.* 2017 Feb;101(2):281-289. doi: 10.1002/cpt.521. Epub 2016 Nov 17. PubMed PMID: 27648725; PubMed Central PMCID: PMC5260337.
31. Pontes C. New Methods and Designs of Clinical Trials. *Clin Ther.* 2016 Oct 6;38(10S):e2-e3. doi: 10.1016/j.clinthera.2016.07.018. PubMed PMID: 27673628.
32. Serra M, Vives R, Cañellas M, Planell J, Oliva JC, Colilles C, Pontes C. Outpatient multimodal intravenous analgesia in patients undergoing day-case surgery: description of a three year experience. *BMC Anesthesiol.* 2016 Sep 13;16:78. doi: 10.1186/s12871-016-0246-6. PubMed PMID: 27619387; PubMed Central PMCID: PMC5020512.
33. Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. *J Antimicrob Chemother.* 2016 Jun;71(6):1651-9. doi: 10.1093/jac/dkv503. Epub 2016 Feb 10. PubMed PMID: 26869692.
34. Ulldemolins M, Soy D, Llauradó-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. *Antimicrob Agents Chemother.* 2015 Sep;59(9):5520-8. doi: 10.1128/AAC.00712-15. Epub 2015 Jun 29. PubMed PMID: 26124172; PubMed Central PMCID: PMC4538468.
35. Vives R, Pontes C, Sarasa M, Millier A. Safety and Activity of UR-1505 in Atopic Dermatitis: A Randomized, Double-blind Phase II Exploratory Trial. *Clin Ther.* 2015 Sep 1;37(9):1955-65. doi: 10.1016/j.clinthera.2015.06.005. Epub 2015 Jul 7. PubMed PMID: 26163200.
36. Wilken R, Li CS, Sharon VR, Kim K, Patel FB, Patel F, Maverakis E. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. *Trials.* 2015 Aug 22;16:374. doi: 10.1186/s13063-015-0879-7. PubMed PMID: 26297574; PubMed Central PMCID: PMC4546316.
37. Other citationsPrivate
38. Pontes C, Gratacós J, Torres F, Avendaño C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmartí R, Calvo G. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. *Trials.* 2015 Aug 20;16:370. doi: 10.1186/s13063-015-0828-5. PubMed PMID: 26289076; PubMed Central PMCID: PMC4546086.
39. Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, Bernal-Sprekelsen M. A randomised double blind clinical trial to compare surgical field bleeding during endoscopic sinus surgery with clonidine-based or remifentanyl-based hypotensive anaesthesia. *Rhinology.* 2015 Jun;53(2):107-15. doi: 10.4193/Rhin14.185. PubMed PMID: 26030032.
40. Pontes C, Vives R, Torres F, Panés J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. *Inflamm Bowel Dis.* 2014 Nov;20(11):2004-12. doi: 10.1097/MIB.000000000000166. PubMed PMID: 25192498.
41. Pallero M, Puy C, Güell R, Pontes C, Martí S, Torres F, Antón A, Muñoz X. Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: a randomized trial with cost assessment. *Respir Med.* 2014 Jul;108(7):1014-22. doi: 10.1016/j.rmed.2014.04.016. Epub 2014 May 2. PubMed PMID: 24837977.
42. Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo G, Soy D, Martín-Loeches I. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. *Crit Care.* 2014 Jun 23;18(3):227. doi: 10.1186/cc13938. Review. PubMed PMID: 25042938; PubMed Central PMCID: PMC4075152.
43. Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, Bernal-Sprekelsen M. Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study. *Eur Arch Otorhinolaryngol.* 2014 Jun;271(6):1505-11. doi: 10.1007/s00405-013-2700-0. Epub 2013 Sep

20. PubMed PMID: 24052249.
44. Torres F, Pontes C. [Missing data: warrant for search and capture]. *Med Clin (Barc)*. 2013 Oct 5;141(7):297-9. doi: 10.1016/j.medcli.2013.04.001. Epub 2013 May 22. PubMed PMID: 23706686.
45. Román J, Planell N, Lozano JJ, Aceituno M, Esteller M, Pontes C, Balsa D, Merlos M, Panés J, Salas A. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. *Inflamm Bowel Dis*. 2013 Feb;19(2):221-9. doi: 10.1002/ibd.23020. PubMed PMID: 22605655.
46. Salcedo C, Pontes C, Merlos M. Is the H4 receptor a new drug target for allergies and asthma?. *Front Biosci (Elite Ed)*. 2013 Jan 1;5:178-87. doi: 10.2741/e606. Review. PubMed PMID: 23276980.
47. Avendaño Solá C, Delgadillo Duarte J, de Abajo FJ, Sanz N. [Changes in the European normative of clinical trials (ii): towards a proportional and risk-adapted regulation]. *Med Clin (Barc)*. 2012 May 12;138(13):574-8. doi: 10.1016/j.medcli.2011.12.010. Epub 2012 Mar 6. PubMed PMID: 22401737.
48. Avendaño Solá C, Delgadillo Duarte J, Pontes García C, Cabrera García L. [Changes in the European normative of clinical trials (i): a chance to improve the paperwork authorization]. *Med Clin (Barc)*. 2012 Apr 28;138(11):493-7. doi: 10.1016/j.medcli.2011.12.008. Epub 2012 Mar 6. PubMed PMID: 22401721.
49. Cooper C, Steinbuch M, Stevenson R, Miday R, Watts NB. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. *Osteoporos Int*. 2010 Apr;21(4):569-77. doi: 10.1007/s00198-009-1003-1. Epub 2009 Jun 23. PubMed PMID: 19547906; PubMed Central PMCID: PMC2832873.
50. Other citationsPrivate
51. Torres F, Calvo G, Pontes C. [Methodological recommendations of the Regulatory Agencies]. *Med Clin (Barc)*. 2005 Dec 1;125 Suppl 1:72-6. doi: 10.1016/s0025-7753(05)72213-2. Review. PubMed PMID: 16464431.
52. Marín-Iranzo R, de la Sierra-Iserte A, Roca-Cusachs A, Oliván-Martínez J, Redón-Mas J, Luque-Otero M, de la Figuera-von Wichman M, Pontes-García C, Delgadillo-Duarte J. [Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlodipine dose in essential hypertensive patients not controlled with amlodipine 5 mg]. *Rev Clin Esp*. 2005 Sep;205(9):418-24. doi: 10.1157/13079069. PubMed PMID: 16194475.
53. Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, Cambray M, Capellà G, Canzian F. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1633-8. doi: 10.1158/1055-9965.EPI-05-0057. PubMed PMID: 16030094.
54. Menéndez M, González S, Blanco I, Guinó E, Peris M, Peinado MA, Capellà G, Moreno V. Colorectal cancer risk and the APC D1822V variant. *Int J Cancer*. 2004 Oct 20;112(1):161-3. doi: 10.1002/ijc.20361. PubMed PMID: 15305389.
55. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. *Br J Cancer*. 2004 Jul 19;91(2):339-43. doi: 10.1038/sj.bjc.6601906. PubMed PMID: 15173859; PubMed Central PMCID: PMC2409800.
56. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. *Neurology*. 2004 Apr 13;62(7):1073-80. doi: 10.1212/01.wnl.0000113757.34662.aa. PubMed PMID: 15079004.
57. de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. *J Hum Hypertens*. 2004 Mar;18(3):215-22. doi: 10.1038/sj.jhh.1001655. PubMed PMID: 14973517.
58. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F.

- Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. *Cancer Res.* 2003 Jul 1;63(13):3560-6. PubMed PMID: 12839942.
59. Aramendi JI, Mestres CA, Campos V, Martínez-León J, Pontes C, Muñoz G, Navas JC. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): rationale and design for a prospective, randomized, co-operative trial. *Interact Cardiovasc Thorac Surg.* 2003 Jun;2(2):170-4. doi: 10.1016/S1569-9293(03)00010-0. PubMed PMID: 17670019.
60. Antoñanzas F, Velasco M, Abbas I, Pontes C, Delgado J, Terán M. [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension]. *Aten Primaria.* 2003;31(6):366-71. doi: 10.1016/s0212-6567(03)70700-8. PubMed PMID: 12716571.
61. Darbà J, Izquierdo I, Pontes C, Navas C, Rovira J. Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. *Pharmacoeconomics.* 2002;20(3):195-201. doi: 10.2165/00019053-200220030-00005. PubMed PMID: 11929349.
62. del Palacio A, Sanz F, Sánchez-Alor G, Garau M, Calvo MT, Boncompte E, Algueró M, Pontes C, Gómez de la Cámara A. Double-blind randomized dose-finding study in acute vulvovaginal candidosis. Comparison of flutrimazole site-release cream (1, 2 and 4%) with placebo site-release vaginal cream. *Mycoses.* 2000 Oct;43(9-10):355-65. doi: 10.1046/j.1439-0507.2000.00575.x. PubMed PMID: 11105539.
63. Cruz-Fernández JM, López-Bescós L, García-Dorado D, López García-Aranda V, Cabadés A, Martín-Jadraque L, Velasco JA, Castro-Beiras A, Torres F, Marfil F, Navarro E. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. *Eur Heart J.* 2000 Mar;21(6):457-65. doi: 10.1053/ehj.1999.1874. PubMed PMID: 10681486.
64. Maillard MP, Rossat J, Nussberger J, Ramis J, Pontes C, Burnier M, Brunner HR. Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. *J Cardiovasc Pharmacol.* 2000 Mar;35(3):383-9. doi: 10.1097/00005344-200003000-00006. PubMed PMID: 10710122.
65. Arnau JM, Vallano A, Artigas R, Vallés JA, Agustí A, Colomé E, Pontes C, Diogene E. [Research on drug utilization in primary health care in national journals]. *Aten Primaria.* 1991 Dec;8(11):932-6. PubMed PMID: 1807427.

Projects

Competitive funding

1. Project: Assessment of the clinical utility of an standardized protocol for dose reduction in patients with axial espondylarthritis in persistent clinical remission during treatment with TNF antagonists: a multicenter open-label controlled and randomised trial.

Setting: National

Role: Principal investigator and study coordinator.

Organization: FUNDACIO PARC TAULLI. Sabadell, Cataluña, España

Funding: MINISTERIO DE SANIDAD Y CONSUMO (Ayudas para el Fomento de la Investigación Clínica Independiente. Cód. según financiadora: EC11-229.

Dates: 01/01/2012 to 01/12/2014 (ongoing)

Other institutions: 31 Spanish sites.

2. Project: Advances in Small Trials dEsign for Regulatory Innovation and eXcelence (ASTERIX)

Setting: European Union

Role: Investigator - WP5

Organization: Universitat Autònoma de Barcelona. Barcelona, Cataluña, España

Funding: FP7-HEALTH-2013-INNOVATION-1

Dates: 01/10/2013 to 30/09/2017

Other institutions: Academic Medical Center Amsterdam; Medizinische Hochschule

Hannover; Medizinische Universitaet Wien; Statisticians in the Pharmaceutical Industry.; Universitat Autònoma de Barcelona; Vereniging Samenwerkende Ouder- en Patiëntenorganisaties betrokken bij

Erfelijkheidsvraagstukken; University Medical Center Utrecht

Project: Study of prognostic biomarkers and predictors of response to antiTNF treatment in patients with axial spondyloarthritis.

Setting: Spain

Role: Co-investigator

Organization: Hospital de Sabadell - Universitat Autònoma de Barcelona

Funding: MINISTERIO DE SANIDAD Y CONSUMO (Ayudas para proyectos de investigación en salud de la convocatoria 2013 de la acción estratégica en salud 2014-2016) - funding code:

PI13/02680

Period: 01-01-2014 to 31-12-2016

Other institutions: 31 Spanish sites.

3. Project: Pharmacokinetic and pharmacodynamic study of the most frequently used wide spectrum antibiotics in the intensive care unit (piperacillin/tazobactam, meropenem, ceftriaxone) in patients with septic shock undergoing high flow renal replacement.

Setting: Nacional

Role: Investigator

Organization: FUNDACIO PARC TAULI, Sabadell, Cataluña, España

funding: MINISTERIO DE SANIDAD Y CONSUMO Ciudad: España (Ayudas para el Fomento de la Investigación Clínica Independiente. Cód. según financiadora: EC11-226)

Dates: 01/01/2012 to 01/12/2014 (ongoing)

Other institutions: 4 University hospitals.

4. Project: Multicenter prospective clinical trial with random allocation to parallel groups to compare the efficacy of the home based vs hospital based adaptation to non-invasive domiciliary mechanical ventilation in patients with chronic respiratory insufficiency secondary to neuromuscular diseases or thoracic deformations.

setting: Nacional

Role: Investigador/a

Organization: Hospital Universitario Vall d'Hebron. Barcelona, Cataluña, España

Funding: Beca Abelló-Linde Cód. según financiadora: Beca 2003

Dates: 01/09/2002 to 01/09/2006

Other institutions: 2 University Hospitals.

Memberships

Registered physician (Collegi Oficial Metges de Barcelona) since June 1990; No 27,246.

Member of Independent Ethic's Committee (Comité Ético de Investigación Clínica de la Corporació Sanitària Parc Taulí) since 01/03/2011 to 28/02/2019.

Member of the Council of the European Association of Clinical Pharmacology and Therapeutics since 2005 to currently. Member of EACPT since 1996.

Member of the Spanish Society of Clinical Pharmacology since 1991; Member of the Executive Committee Oct 2002- Oct 2008.

Member of the Editorial Board of Investigación Clínica y Bioética (ICB), from Oct 2002 to Oct 2008.

Member of the Scientific-technical board for the assessment of applications to public grants Ayudas para el fomento de la investigación clínica independiente, Ministerio de Salud, Política Social e Igualdad Spanish Government (2010 and 2011).

Other Relevant Information

Direction of PhD projects:

Universitat de Barcelona, PhD in Medicine: Alda Cardesin Revilla Maneuvers aimed at minimizing the bleeding of the surgical field during nasosinus endoscopic surgery: randomized clinical trial of the use of an adrenergic alpha agonist hypotensive drug. 23/01/2015 Excel-lent Cum Laude.

Directors: Caridad Pontes, Manuel Bernal-Sprekelsen.

Universitat Autònoma de Barcelona, PhD in Pharmacology: Maria Queralt Gorgas Torner Evaluation of the prevalence of use of drugs in patients who attend a hospital emergency service with fractures due to bone fragility. 02/02/2016 Excel-lent Cum Laude.

Directors: Caridad Pontes, Dolors Capellà Hereu,

Universitat Autònoma de Barcelona, PhD in Pharmacology: Roser Vives Vilagut Design of an exploratory development plan for the assessment of the activity of drugs for the treatment of chronic inflammatory dermatological diseases. 25/11/2016 Excel-lent Cum Laude.

Directors: Caridad Pontes

Universitat Autònoma de Barcelona, PhD in Pharmacology: Mónica Gómez-Valent Proposal for a new classification of orphan and/or rare conditions based on clinical characteristics that determine the applicability of different research methods to their study.07/07/2017 Excel-lent Cum Laude

Directors: Caridad Pontes

Universitat Autònoma de Barcelona, PhD in Pharmacology: Juan Manuel Fontanet Sacristán Study to characterize the designs of clinical trials conducted with orphan medicinal products. 14/09/2017 - Excel-lent Cum Laude

Directors: Caridad Pontes, Josep Torrent Farnell.

Universitat Autònoma de Barcelona, PhD in Pharmacology: Arantxa Sancho Lopez Validation of new designs applied to the study of orphan drugs: clinical and regulatory impact. 23/11/2018- Excel-lent Cum Laude

Directors: Caridad Pontes, Ferran Torres

Universitat Autònoma de Barcelona, PhD in Pharmacology: Yolanda Escamilla Carpintero Selection of the most appropriate alpha 2 agonist as an anesthetic adjuvant in nasosinusal endoscopic surgery: a randomized clinical trial with clonidine versus dexmedetomidine. 25/10/2018- Excel-lent Cum Laude

Directors: Caridad Pontes, Alda Cardesin, Manuel Bernal-Sprekelsen.

Editorial experience

- Editorial coordinator: Investigación Clínica y Bioética, 01/11/2010 to 01/11/2011
- Member of the editorial board: Investigación Clínica y Bioética de 01/11/2002 al 01/11/2011
- Peer reviewer: Arzneimittel Forschung / Drug Research ,Archivos de Bronconeumología, Basic & Clinical Pharmacology and Toxicology, Clinical_Therapeutics, Clinical_Epidemiology, Heliyon, Journal of Pain Research, Medicina Legal, Therapeutics_and_Clinical_Risk_Management, Trials.

Spanish and Catalan: native languages.

English: fluent spoken and written.